https://www.bioworld.com/rss en-us Klebsiella pneumoniae and Acinetobacter baumannii are both major contributors to the global antimicrobial resistance crisis, causing rapidly progressive and often severe infections. Researchers from Vaxdyn SL and collaborators presented efficacy data for K-Vax, an inactivated, LPS-null whole-cell A. baumannii-based vaccine engineered to display conserved K. pneumoniae outer-membrane proteins on the bacterial cell surface. Klebsiella pneumoniae and Acinetobacter baumannii are both major contributors to the global antimicrobial resistance crisis, causing rapidly progressive and often severe infections. Researchers from Vaxdyn SL and collaborators presented efficacy data for K-Vax, an inactivated, LPS-null whole-cell A. baumannii-based vaccine engineered to display conserved K. pneumoniae outer-membrane proteins on the bacterial cell surface.]]> http://www.bioworld.com/articles/730554 Wed, 22 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730554-k-vax-shows-broad-protection-across-circulating-emk-pneumoniae-em-strains At the recent European Society of Clinical Microbiology and Infectious Diseases (ESCMID) meeting in Vienna, Longhorn Vaccines & Diagnostics LLC presented data on the neutralizing antibody responses of LHNVD-202, an unconjugated composite peptide vaccine. http://www.bioworld.com/articles/719270 Wed, 16 Apr 2025 09:00:00 -0400 https://www.bioworld.com/articles/719270-preclinical-data-on-new-composite-peptide-vaccine-from-longhorn Scientist with vial New treatment options for treating Mycobaterium abscessus infections are needed. Previous findings had identified the leucyl-tRNA synthetase inhibitor MRX-6038 to have significant activity against M. abscessus. The aim of this new study was to focus on the activity of MRX-5, the oral prodrug of MRX-6038, both in vivo and in vitro. Mycobaterium abscessus infections are needed. Previous findings had identified the leucyl-tRNA synthetase inhibitor MRX-6038 to have significant activity against M. abscessus. The aim of this new study was to focus on the activity of MRX-5, the oral prodrug of MRX-6038, both in vivo and in vitro.]]> http://www.bioworld.com/articles/708378 Thu, 09 May 2024 09:00:00 -0400 https://www.bioworld.com/articles/708378-mrx-5-to-treat-emmycobacterium-abscessus-em-infections There is a compelling need to produce new antibiotics that hamper severe opportunistic infections, especially in immunocompromised individuals, such as those caused by gram-negative Pseudomonas aeruginosa. Pseudomonas aeruginosa.]]> http://www.bioworld.com/articles/708172 Mon, 06 May 2024 09:00:00 -0400 https://www.bioworld.com/articles/708172-activity-and-mechanism-of-action-of-antibiotic-potentiator-js-238 Pseudomonas aeruginosa Computer-generated image of Pseudomonas aeruginosa bacteria. Credit: U.S. CDC - Medical Illustrator Amicetin-inspired inhibitors of the P-site (AIIPS), also known as CZ-02s, are a series of molecules that target and inhibit a unique site of the bacterial ribosome. http://www.bioworld.com/articles/708170 Mon, 06 May 2024 09:00:00 -0400 https://www.bioworld.com/articles/708170-curzas-cz-02188-shows-promising-antibacterial-activity-with-unique-site-ribosomal-targeting Petri dish There is still a need for developing more potent and broadly neutralizing vaccines against SARS-CoV-2 with improved durability. At the recent ESCMID meeting, Astrazeneca plc presented a new mRNA vaccine against the SARS-CoV-2 virus that encodes for self-assembling virus-like particle (VLP) antigens. http://www.bioworld.com/articles/708132 Fri, 03 May 2024 09:00:00 -0400 https://www.bioworld.com/articles/708132-astrazeneca-presents-data-on-mrna-vlp-sars-cov-2-vaccine-in-animal-models Coronavirus, mRNA and syringe Debiopharm International SA has developed and presented a Fabl inhibitor, gofabicin, for the treatment of antibiotic-resistant Neisseria gonorrhoeae. Neisseria gonorrhoeae.]]> http://www.bioworld.com/articles/708086 Thu, 02 May 2024 09:00:00 -0400 https://www.bioworld.com/articles/708086-debiopharm-presents-new-fabl-inhibitor-for-resistant-emneisseria-em Illustration of Neisseria gonorrhoeae Researchers from Tan Tock Seng Hospital presented data from a study investigating the utility of soluble suppressor of tumorigenicity-2 (sST2) as early prognostic biomarker of severe dengue. http://www.bioworld.com/articles/708084 Thu, 02 May 2024 09:00:00 -0400 https://www.bioworld.com/articles/708084-sst2-as-prognostic-biomarker-for-severe-dengue-in-adult-patients Tiger mosquito Current approved antifungal therapies are limited by their associated adverse events. SCY-247 is a new triterpenoid antifungal for intravenous or oral administration that inhibits the glucan synthase enzyme, which is a key member for the fungal cell wall. http://www.bioworld.com/articles/708081 Thu, 02 May 2024 09:00:00 -0400 https://www.bioworld.com/articles/708081-antifungal-scy-247-shows-efficacy-against-emcandida-em-and-emaspergillus-em Aspergillus mold Severe fever with thrombocytopenia syndrome (SFTS) is a tick-borne disease that results from an infection with the SFTS virus, with a case fatality rate of 6.1% to 21.8%. Identifying critically ill patients at the early stages is crucial for clinical management. http://www.bioworld.com/articles/708046 Tue, 30 Apr 2024 09:00:00 -0400 https://www.bioworld.com/articles/708046-mcp-3-predicts-prognosis-of-severe-fever-with-thrombocytopenia-syndrome Illustration of tick penetrating skin into blood stream Researchers from Longhorn Vaccines & Diagnostics LLC have presented data at the ongoing ESCMID conference regarding their unconjugated multiepitope vaccine against influenza, LHNVD-105. http://www.bioworld.com/articles/707999 Mon, 29 Apr 2024 09:00:00 -0400 https://www.bioworld.com/articles/707999-longhorns-lhnvd-105-shows-strong-immunization-against-influenza-virus-in-pigs Viruses About 25% of subjects with West Nile virus (WNV) infection develop fever and about 1% have neuroinvasive disease. Recent research has proposed measuring CD169 in peripheral blood (monocyte/lymphocyte ratio) as a marker of viral infections. The usefulness of monocyte CD169 (mCD169) in peripheral blood was tested in subjects with active WNV infection. http://www.bioworld.com/articles/707997 Mon, 29 Apr 2024 09:00:00 -0400 https://www.bioworld.com/articles/707997-cd169-is-a-diagnostic-marker-of-west-nile-virus-infection New trial results presented by Shionogi & Co. Ltd. at the 32nd European Congress of Clinical Microbiology and Infectious Diseases showed the company’s 3CL protease inhibitor, S-217622, was well-tolerated, with the potential to rapidly clear SARS-CoV-2, Simon Portsmouth, executive medical director at Shionogi, told BioWorld. BioWorld.]]> http://www.bioworld.com/articles/518448 Tue, 03 May 2022 13:00:00 -0400 https://www.bioworld.com/articles/518448-shionogi-releases-positive-results-back-on-track-for-covid-19-treatment New trial results presented by Shionogi & Co. Ltd. at the 32nd European Congress of Clinical Microbiology and Infectious Diseases showed the company’s 3CL protease inhibitor, S-217622, was well-tolerated, with the potential to rapidly clear SARS-CoV-2, Simon Portsmouth, executive medical director at Shionogi, told BioWorld. BioWorld.]]> http://www.bioworld.com/articles/518301 Wed, 27 Apr 2022 12:00:00 -0400 https://www.bioworld.com/articles/518301-shionogi-releases-positive-results-back-on-track-for-covid-19-treatment Antibiotics drugs discovery, Ursula Theuretzbacher told the audience at the 2022 European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), has more than one challenge to overcome. http://www.bioworld.com/articles/518243 Tue, 26 Apr 2022 12:00:00 -0400 https://www.bioworld.com/articles/518243-eccmid-2022-in-antibiotic-development-scientific-ingenuity-meets-a-dysfunctional-marketplace Antibiotic resistant bacteria inside a biofilm